20% N2O
NIDA-08391-1
Phase 2 small_molecule completed
Quick answer
20% N2O for Opioid-Related Disorders is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Opioid-Related Disorders
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed